Centinel Spine has received FDA approval for two-level use of its prodisc C Nova cervical artificial disc replacement device.
The approval gives the company three cervical disc replacement devices cleared for both one- and two-level procedures, according to an Oct. 14 news release.
Centinel Spine’s prodisc C Vivo and prodisc C SK devices received FDA approval for two-level use in October 2025. The expanded portfolio allows surgeons to select among different implant designs based on patient anatomy.
Prodisc C Nova is currently available on a limited-release basis in the U.S.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
